SCHEMBL1924876

SCHEMBL1924876

Cc1ccc(NC(=O)Nc2ccc(-c3c(CCC(=O)O)c[nH]c3C(N)=O)cc2)cc1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT2 P31751 1/20 0.42
KDR P35968 4/20 0.41
LCK P06239 2/20 0.41
BLK P51451 2/20 0.41
ROCK2 O75116 1/20 0.41
MAP4K4 O95819 1/20 0.41
RET P07949 1/20 0.41
PIM1 P11309 1/20 0.41
RPS6KB1 P23443 1/20 0.41
GSK3B P49841 1/20 0.41
PRKCD Q05655 1/20 0.41
PRKAA1 Q13131 1/20 0.41
STK3 Q13188 1/20 0.41
ROCK1 Q13464 1/20 0.41
NTRK3 Q16288 1/20 0.41
TAOK1 Q7L7X3 1/20 0.41
HIPK4 Q8NE63 1/20 0.41
AURKB Q96GD4 1/20 0.41
CDK19 Q9BWU1 1/20 0.41
HIPK2 Q9H2X6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1923912 0.89 KDR (0.48) AKT2KDRSTING1PDGFRBSMN1; SMN2
SCHEMBL1924884 0.89 MEN1 (0.42) AKT2KDRLCKBLKROCK2
SCHEMBL1924795 0.89 CDK8 (0.44) AKT2KDRRETCDK8PDGFRB
SCHEMBL1924534 0.88 AURKA (0.44) AKT2KDRLCKBLKPDGFRB
SCHEMBL1924620 0.88 CSF1R (0.53) KDRLCKBLKROCK2MAP4K4
SCHEMBL1924361 0.86 KMT2A (0.46) ROCK2ALDH1A1MEN1KMT2APOLB
SCHEMBL1925746 0.86 ITGB1 (0.52) KDRALDH1A1PDGFRBSMN1; SMN2MEN1
SCHEMBL1924464 0.85 ALDH1A1 (0.38) AKT2KDRSTING1ALDH1A1PDGFRB
SCHEMBL1926602 0.84 KDM4E (0.46) KDRROCK2PDGFRBSMN1; SMN2MEN1
SCHEMBL1925038 0.84 ROCK2 (0.46) KDRLCKBLKROCK2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856043-B1 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER AVENTIS PHARMA SA (FR) 2011-06-08 EP claimed